CureVac COVID-19 vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CureVac COVID-19 vaccine" in English language version.

refsWebsite

Global rank English rank

8curevac.com

low place

7nih.gov

4^th place

6reuters.com

49^th place

47^th place

5web.archive.org

1^st place

5doi.org

2^nd place

3clinicaltrials.gov

5,225^th place

4,062^nd place

2semanticscholar.org

11^th place

8^th place

1nytimes.com

7^th place

1cdc.gov

218^th place

212^th place

1pharmaceutical-technology.com

low place

1fiercepharma.com

low place

8,921^st place

1clinicaltrialsarena.com

low place

1clinicaltrialsregister.eu

low place

1europa.eu

68^th place

117^th place

1harvard.edu

18^th place

17^th place

1science.org

1,160^th place

737^th place

1who.int

195^th place

302^nd place

cdc.gov

"Understanding mRNA COVID-19 vaccines". US Centers for Disease Control and Prevention. 18 December 2020. Retrieved 5 January 2021.

clinicaltrials.gov

"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. 26 June 2020. Retrieved 15 July 2021.
"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 17 August 2020. Retrieved 12 January 2021.
"A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults". ClinicalTrials.gov. 8 December 2020. NCT04652102. Retrieved 19 December 2020.

clinicaltrialsarena.com

"CureVac's Covid-19 vaccine induces immune response in study". Clinical Trials Arena. 3 November 2020. Retrieved 5 January 2021.

clinicaltrialsregister.eu

"Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older". EU Clinical Trials Register. 19 November 2020. Retrieved 5 January 2021. Proposed INN: zorecimeran

curevac.com

"CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide". CureVac (Press release). 15 March 2020. Archived from the original on 8 March 2021. Retrieved 17 February 2021.
"CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV". 16 June 2021. Archived from the original on 24 June 2021. Retrieved 17 June 2021.
"CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60". CureVac (Press release). 30 June 2021. Archived from the original on 12 October 2021. Retrieved 2 July 2021.
"mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents" (PDF). Archived (PDF) from the original on 4 June 2021. Retrieved 22 July 2021.
"COVID-19". CureVac. Retrieved 21 December 2020.
"CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV". CureVac (Press release). 7 January 2021. Retrieved 17 February 2021.
"CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV". CureVac (Press release).
"Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac's COVID-19 Vaccine Candidate, CVnCoV". CureVac (Press release). 30 March 2021. Retrieved 14 April 2021.

doi.org

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (November 2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. PMC 3597572. PMID 23064118.
Dolgin E (November 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology: d41587–020–00022-y. doi:10.1038/d41587-020-00022-y. PMID 33239758. S2CID 227176634.
Kartoglu U, Milstien J (July 2014). "Tools and approaches to ensure quality of vaccines throughout the cold chain". Expert Review of Vaccines. 13 (7): 843–54. doi:10.1586/14760584.2014.923761. PMC 4743593. PMID 24865112.
Hanson CM, George AM, Sawadogo A, Schreiber B (April 2017). "Is freezing in the vaccine cold chain an ongoing issue? A literature review". Vaccine. 35 (17): 2127–2133. doi:10.1016/j.vaccine.2016.09.070. PMID 28364920.
Dolgin E (June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.

europa.eu

ema.europa.eu

"EMA starts rolling review of CureVac's COVID-19 vaccine (CVnCoV)". European Medicines Agency (EMA) (Press release). 11 February 2021. Retrieved 12 February 2021.

fiercepharma.com

Kansteiner F (17 November 2020). "CureVac, armed with COVID-19 vaccine deal, plots 'pandemic-scale' Euro manufacturing expansion". FiercePharma, Questex LLC. Retrieved 5 January 2021.

harvard.edu

ui.adsabs.harvard.edu

Dolgin E (June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.

nih.gov

pubmed.ncbi.nlm.nih.gov

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (November 2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. PMC 3597572. PMID 23064118.
Dolgin E (November 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology: d41587–020–00022-y. doi:10.1038/d41587-020-00022-y. PMID 33239758. S2CID 227176634.
Kartoglu U, Milstien J (July 2014). "Tools and approaches to ensure quality of vaccines throughout the cold chain". Expert Review of Vaccines. 13 (7): 843–54. doi:10.1586/14760584.2014.923761. PMC 4743593. PMID 24865112.
Hanson CM, George AM, Sawadogo A, Schreiber B (April 2017). "Is freezing in the vaccine cold chain an ongoing issue? A literature review". Vaccine. 35 (17): 2127–2133. doi:10.1016/j.vaccine.2016.09.070. PMID 28364920.
Dolgin E (June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.

ncbi.nlm.nih.gov

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (November 2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. PMC 3597572. PMID 23064118.
Kartoglu U, Milstien J (July 2014). "Tools and approaches to ensure quality of vaccines throughout the cold chain". Expert Review of Vaccines. 13 (7): 843–54. doi:10.1586/14760584.2014.923761. PMC 4743593. PMID 24865112.

nytimes.com

Zimmer C (12 October 2021). "CureVac has withdrawn its Covid vaccine application to European regulators". The New York Times. Retrieved 13 October 2021.

pharmaceutical-technology.com

Nawrat A (3 December 2020). "Q&A with CureVac: resolving the ultra-cold chain logistics of Covid-19 mRNA vaccines". Pharmaceutical Technology. Retrieved 5 January 2021.

reuters.com

Burger L (16 June 2021). "CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy". Reuters. Retrieved 17 June 2021.
Szymanska Z, Burger L (12 October 2021). "CureVac drops COVID-19 vaccine, pins hope on next-generation shots". Reuters. Retrieved 30 December 2021.
"Tesla to make molecule printers for German COVID-19 vaccine developer CureVac". Reuters. 2 July 2020. Retrieved 19 December 2020.
"CureVac's COVID-19 vaccine triggers immune response in Phase I trial". Reuters. 2 November 2020. Retrieved 5 January 2021.
Burger L (7 January 2021). "CureVac strikes COVID-19 vaccine alliance with Bayer". Reuters. Retrieved 17 February 2021.
"CureVac starts review process in Switzerland for COVID-19 vaccine hopeful". Reuters. 19 April 2021. Retrieved 19 April 2021.

science.org

Cohen J (18 June 2021). "What went wrong with CureVac's highly anticipated new mRNA vaccine for COVID-19?". Science AAAS. Retrieved 6 August 2021.

semanticscholar.org

api.semanticscholar.org

Dolgin E (November 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology: d41587–020–00022-y. doi:10.1038/d41587-020-00022-y. PMID 33239758. S2CID 227176634.
Dolgin E (June 2021). "CureVac COVID vaccine let-down spotlights mRNA design challenges". Nature. 594 (7864): 483. Bibcode:2021Natur.594..483D. doi:10.1038/d41586-021-01661-0. PMID 34145413. S2CID 235480198.

web.archive.org

"CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide". CureVac (Press release). 15 March 2020. Archived from the original on 8 March 2021. Retrieved 17 February 2021.
"CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV". 16 June 2021. Archived from the original on 24 June 2021. Retrieved 17 June 2021.
"CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60". CureVac (Press release). 30 June 2021. Archived from the original on 12 October 2021. Retrieved 2 July 2021.
"mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents" (PDF). Archived (PDF) from the original on 4 June 2021. Retrieved 22 July 2021.
World Health Organization (October 2020). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition)" (PDF). WHO Drug Information. 34 (3): 668–69. Archived (PDF) from the original on 27 November 2020.

who.int

World Health Organization (October 2020). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 124 – COVID-19 (special edition)" (PDF). WHO Drug Information. 34 (3): 668–69. Archived (PDF) from the original on 27 November 2020.